Abingdon Health Secures European Patent for Innovative Smartphone-Based Diagnostics

Abingdon Health PLC ( (GB:ABDX) ) has shared an announcement.

Abingdon Health PLC has secured a European patent for its AppDx® lateral flow smartphone reader, which enables the analysis of lateral flow test results via a smartphone’s camera using advanced image processing and deep learning algorithms. This patent further strengthens the company’s intellectual property portfolio and highlights its innovative role in the lateral flow diagnostics industry, supporting its customers with cutting-edge technologies and reinforcing its market positioning.

The most recent analyst rating on (GB:ABDX) stock is a Hold with a £7.00 price target. To see the full list of analyst forecasts on Abingdon Health PLC stock, see the GB:ABDX Stock Forecast page.

Spark’s Take on GB:ABDX Stock

According to Spark, TipRanks’ AI Analyst, GB:ABDX is a Neutral.

Abingdon Health PLC’s overall score is driven by its strong business development activities and promising revenue growth, albeit overshadowed by persistent profitability challenges and valuation concerns. Technical indicators suggest a neutral outlook, while recent corporate events present potential for future growth.

To see Spark’s full report on GB:ABDX stock, click here.

More about Abingdon Health PLC

Abingdon Health PLC is a leading med-tech contract service provider specializing in the development, manufacturing, and regulatory support of rapid diagnostic tests, particularly lateral flow assays. The company serves international markets, offering expertise in areas such as infectious diseases, clinical testing, animal health, and environmental testing. Founded in 2008, it operates from headquarters in York, England, with additional facilities in Doncaster, England, and Madison, Wisconsin, USA.

Average Trading Volume: 114,736

Technical Sentiment Signal: Hold

Current Market Cap: £16.95M

See more data about ABDX stock on TipRanks’ Stock Analysis page.